Al Sandrock (Biogen via YouTube)
In search of a post-Tecfidera hit for MS, Biogen follows Sanofi, Roche down the BTK path — and bets $125M cash on a drug out of China
Aduhelm may be hogging the spotlight, but behind the scenes, Biogen’s BD team has apparently looked far and wide to spice up the pipeline. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
